The Ministry of Health of Trinidad and Tobago has issued a voluntary medication recall through its Chemistry, Food and Drug Division, targeting specific production batches of combined bisoprolol fumarate and hydrochlorothiazide tablets. This generic pharmaceutical product is primarily prescribed for hypertension management.
The recall affects medication from lots numbered 17232401 (with expiration November 2025) and 17240974 (expiring May 2026). The regulatory action follows quality control testing that revealed trace contamination with ezetimibe, a cholesterol-lowering medication that should not be present in the blood pressure treatment.
This safety initiative originated from Glenmark Pharmaceuticals Inc. in coordination with the United States Food and Drug Administration (FDA). Routine quality assessment procedures identified potential cross-contamination during manufacturing, prompting the voluntary recall of 11,136 medication bottles distributed to pharmacies.
Although the FDA has classified this recall as Class III—indicating that exposure to the trace contaminant is unlikely to cause adverse health consequences—the Ministry recommends precautionary measures. Consumers who have purchased medications from the affected lots should immediately discontinue use and return the products to their point of purchase.
The Ministry emphasizes that patients should not abruptly stop antihypertensive treatment without consulting healthcare professionals. Individuals with health concerns are advised to seek immediate guidance from their medical providers to ensure continuous proper management of their blood pressure conditions.
For additional information, concerned citizens may contact the Office of the Director of the Chemistry, Food and Drugs Division via email at cfdd@health.gov.tt or by telephone at 217-4664 extension 13101.









